Here, we utilized the usually ineffective charged fraction of doxorubicin and shuttled it into cancer cells via cation permeable TRPV2 channels, allowing us to achieve the desired effect using substantially lower doses of doxorubicin. The gene discussed is TRPV2; the disease is cancer.